TY - JOUR
T1 - Enzalutamide after docetaxel and abiraterone therapy in metastatic castration-resistant prostate cancer
AU - Schmid, Sebastian Christoph
AU - Geith, Alexander
AU - Böker, Alena
AU - Tauber, Robert
AU - Seitz, Anna Katharina
AU - Kuczyk, Markus
AU - Von Klot, Christoph
AU - Gschwend, Jürgen Erich
AU - Merseburger, Axel Stuart
AU - Retz, Margitta
N1 - Copyright:
Copyright 2019 Elsevier B.V., All rights reserved.
PY - 2014/2
Y1 - 2014/2
N2 - Introduction: Enzalutamide is a novel antiandrogen which is approved for the treatment of metastatic, castration-resistant prostate cancer (mCRPC) after taxane-based chemotherapy. The efficacy of enzalutamide after the sequence docetaxel and abiraterone is not proven. Methods: Thirty-five mCRPC patients in the German compassionate use program, who received enzalutamide after progression with taxane-based chemotherapy and abiraterone were prospectively evaluated. The endpoints of the study were overall survival, radiologic progression-free survival and safety. Results: The median treatment duration on enzalutamide was 2.8 months. The median overall survival was 7.5 months [95% confidence interval (CI) 4.7-10.3] while median progression-free survival assessed by imaging was 3.1 months (95% CI 1.4-4.8). The most common toxicities of all grades were anemia and weight loss. Conclusion: Although the results are limited by a small patient number, the consecutive use of enzalutamide and abiraterone after taxane-based chemotherapy shows a modest clinical activity. Thus, sequence therapy alternating between chemotherapy and antihormonal drugs might be amore promising approach in mCRPC treatment.
AB - Introduction: Enzalutamide is a novel antiandrogen which is approved for the treatment of metastatic, castration-resistant prostate cancer (mCRPC) after taxane-based chemotherapy. The efficacy of enzalutamide after the sequence docetaxel and abiraterone is not proven. Methods: Thirty-five mCRPC patients in the German compassionate use program, who received enzalutamide after progression with taxane-based chemotherapy and abiraterone were prospectively evaluated. The endpoints of the study were overall survival, radiologic progression-free survival and safety. Results: The median treatment duration on enzalutamide was 2.8 months. The median overall survival was 7.5 months [95% confidence interval (CI) 4.7-10.3] while median progression-free survival assessed by imaging was 3.1 months (95% CI 1.4-4.8). The most common toxicities of all grades were anemia and weight loss. Conclusion: Although the results are limited by a small patient number, the consecutive use of enzalutamide and abiraterone after taxane-based chemotherapy shows a modest clinical activity. Thus, sequence therapy alternating between chemotherapy and antihormonal drugs might be amore promising approach in mCRPC treatment.
UR - http://www.scopus.com/inward/record.url?scp=84899096462&partnerID=8YFLogxK
U2 - 10.1007/s12325-014-0092-1
DO - 10.1007/s12325-014-0092-1
M3 - Journal articles
C2 - 24442834
AN - SCOPUS:84899096462
SN - 0741-238X
VL - 31
SP - 234
EP - 241
JO - Advances in Therapy
JF - Advances in Therapy
IS - 2
ER -